Liver cell transplantation for the treatment of liver based metabolic diseases.

肝细胞移植用于治疗肝脏代谢疾病。

• 批准号: nhmrc : 491256
• 负责人: Dr Heidi Peters
• 金额: $ 29.62万
• 依托单位: Murdoch Childrens Research Institute
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Project Grants
• 财政年份: 2008
• 资助国家: 澳大利亚
• 起止时间: 2008-01-01 至 2010-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/liver-cell-transplantation-metabolic-diseases/77987
• 关键词: Liver; cell; transplantation; treatment; liver

We propose to investigate the role of liver cell transplantation (LCT) for the therapy of inherited liver-based metabolic diseases using a methylmalonic aciduria (MMA) mouse model. LCT provides an exciting alternative to whole organ transplantation. Initially it was considered liver cells would be immunopriviledged. This has not proven to be the case. Immune modulation will be important. We will also examine immune modulation using antibodies to optimise longterm survival of allogeneic cells.

我们建议使用甲基丙二酸尿症（MMA）小鼠模型研究肝细胞移植（LCT）在治疗遗传性肝代谢疾病中的作用。LCT为整个器官移植提供了一种令人兴奋的替代方案。最初，人们认为肝细胞是免疫保护的。事实证明并非如此。免疫调节将是重要的。我们还将研究使用抗体的免疫调节，以优化同种异体细胞的长期存活。